PAR - 416 mill MC
RAC - 423 mill MC
OPT - 456 mill MC
NEU - 260 mill MC
IXC - 49 mill MC
Even if it got to NEU say, thats 5 x from here or $3.50 share price. Get real punters, this is the biggest gift on the ASX. Wait in 2 years time when we will say to ourselves, I cant believe how obvious this was, wish I bought more.
Dr Duthy also noted that comparable companies on the ASX which are either repurposing approved therapies, developing orphan drugs, or developing ophthalmology therapies, such asParadigm Biopharmaceuticals (ASX: PAR),Opthea (ASX: OPT),Race Oncology (ASX: RAC)orNeuren Pharmaceuticals (ASX: NEU), are priced significantly higher despite similar stages of development.
Patience people patience
Ann: Invex Granted Key European Patent for Exenatide, page-45
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125000 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 16.12pm 15/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable